Information for consumers
The drugs CellCept and MYFORTIC are both used after kidney transplantation to help prevent organ rejection. CellCept is also used after heart and liver transplantation to help prevent organ rejection.
Women and men taking either of these products should understand the risk of harm to the baby, the need for effective contraception, and the need to immediately consult a physician if there is a possibility of a pregnancy.
Consumers with any questions about their CellCept or MYFORTIC treatment should contact their healthcare professional for more information.
Information for health care professionals
Before the start of treatment with mycophenolate-containing products, female and male patients of reproductive potential should be made aware of the increased risk of pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention, and planning.
Before starting therapy with any mycophenolate-containing product, women of childbearing potential must have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL; the second test should be performed 8 to 10 days after the first one and immediately before starting any mycophenolate-containing product. Repeat pregnancy tests should be performed during routine follow-up visits. Results of all pregnancy tests should be discussed with the patient. Patients should be instructed to consult their physician immediately should pregnancy occur.
Women of child bearing potential should use two reliable forms of contraception simultaneously, including at least one highly effective method, before beginning mycophenolate therapy, during therapy, and for six weeks following discontinuation of therapy, unless abstinence is the chosen method of contraception.
Sexually active men should be informed to use condoms during treatment and for at least 90 days after cessation of treatment. Condom use applies for both reproductively competent and vasectomized men, because the risks associated with the transfer of seminal fluid also apply to men who have had a vasectomy. Men should be informed not to donate sperm/semen during therapy or for at least 90 days following discontinuation of mycophenolate. In addition, female partners of male patients should be informed to use highly effective contraception during treatment and for a total of 90 days after the last dose of any mycophenolate containing product.
Patients should be informed not to donate blood during treatment or for at least 6 weeks following discontinuation of any mycophenolate-containing product.
Action taken by Health Canada
Health Canada, in collaboration with Hoffmann-La Roche Limited and Novartis Pharmaceuticals Canada Inc., is communicating this important safety information to health care professionals and to the public through its
Healthy Canadians Web site and MedEffect
TM e-Notice.
Health Canada is working with Hoffmann-La Roche Limited and Novartis Pharmaceuticals Canada Inc., to update the Canadian Product Monographs for their respective products to include these contraindications.